

Serial No.: 10/070,479  
Group Art Unit No.: 1648

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-20 (Cancelled).

21. (Currently amended): A ~~vaccine~~ composition comprising:

- (a) a herpes simplex virus (~~HSV~~) gD antigen; and
- (b) a human papillomavirus (~~HPV~~) L1 antigen

in conjunction with an adjuvant which is a preferential stimulator of TH1 cell response.

22. (Previously presented): A ~~vaccine~~ composition according to claim 21 which additionally comprises a carrier.

23. (Previously presented): A ~~vaccine~~ composition according to claim 21 in which the preferential stimulator of TH1-cell response is selected from the group of adjuvants comprising: 3D-MPL, 3D-MPL wherein the size of the particles of 3D-MPL is preferably about or less than 100nm, QS21, a mixture of QS21 and cholesterol, and a CpG oligonucleotide.

24. (Previously presented): A ~~vaccine~~ composition according to claim 23 in which the preferential stimulator of TH1-cell response is 3D-MPL.

25. (Previously presented): A ~~vaccine~~ composition according to claim 21 in which the HSV antigen is HSV-2 gD or a truncate thereof.

26. (Currently amended): A ~~vaccine~~ composition according to claim 21 ~~which comprises at least one HPV antigen selected from the group consisting of L1, L2, E6 and E7, optionally in the form of a fusion protein and/or a truncate~~ wherein the human papillomavirus L1 antigen is in the form of a virus-like particle.

Claims 27-70 (Cancelled).